How many insider trades does FilingIQ track for ESPR?

FilingIQ tracks 317 Form 4 insider transactions for ESPR (Esperion Therapeutics, Inc.), covering filings from Feb 18, 2015 onwards. 9 of those were filed in the last 90 days.

Are ESPR insiders net buyers or net sellers?

Across the full Form 4 history for ESPR, 44 transactions (14%) were open-market purchases and 116 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ESPR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ESPR in?

Esperion Therapeutics, Inc. (ESPR) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $837.92M.

ESPR insider trading

NasdaqGM Healthcare

Esperion Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

317

Last 90 days

Buys / sells

14% / 37%

Market cap

$837.92M

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Company website: www.esperion.com

ESPR insider activity at a glance

FilingIQ has scored 317 insider transactions for ESPR since Feb 18, 2015. The most recent filing in our index is dated Mar 17, 2026.

Across the full history, 44 open-market purchases and 116 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ESPR insider trades is 53.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ESPR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ESPR?: FilingIQ tracks 317 Form 4 insider transactions for ESPR (Esperion Therapeutics, Inc.), covering filings from Feb 18, 2015 onwards. 9 of those were filed in the last 90 days.
Are ESPR insiders net buyers or net sellers?: Across the full Form 4 history for ESPR, 44 transactions (14%) were open-market purchases and 116 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ESPR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ESPR in?: Esperion Therapeutics, Inc. (ESPR) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $837.92M.

Methodology & sources

Every ESPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.